[go: up one dir, main page]

AR095890A1 - Uso de ácido trifluoroacético y sales del mismo para tratar la hipercolesterolemia - Google Patents

Uso de ácido trifluoroacético y sales del mismo para tratar la hipercolesterolemia

Info

Publication number
AR095890A1
AR095890A1 ARP140101631A ARP140101631A AR095890A1 AR 095890 A1 AR095890 A1 AR 095890A1 AR P140101631 A ARP140101631 A AR P140101631A AR P140101631 A ARP140101631 A AR P140101631A AR 095890 A1 AR095890 A1 AR 095890A1
Authority
AR
Argentina
Prior art keywords
trifluoroacetic acid
salts
same
treat hypercholesterolemia
hypercholesterolemia
Prior art date
Application number
ARP140101631A
Other languages
English (en)
Inventor
Bulgheroni Anna
Legora Michela
Ceriani Daniela
Mailland Federico
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of AR095890A1 publication Critical patent/AR095890A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Ácido trifluoroacético y sus sales fisiológicamente aceptables para usar en el tratamiento de la hipercolesterolemia.
ARP140101631A 2013-04-22 2014-04-16 Uso de ácido trifluoroacético y sales del mismo para tratar la hipercolesterolemia AR095890A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13164730.7A EP2796135A1 (en) 2013-04-22 2013-04-22 Use of trifluoroacetic acid and salts thereof to treat hypercholesterolemia

Publications (1)

Publication Number Publication Date
AR095890A1 true AR095890A1 (es) 2015-11-18

Family

ID=48141842

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101631A AR095890A1 (es) 2013-04-22 2014-04-16 Uso de ácido trifluoroacético y sales del mismo para tratar la hipercolesterolemia

Country Status (4)

Country Link
EP (1) EP2796135A1 (es)
AR (1) AR095890A1 (es)
TW (1) TW201521716A (es)
WO (1) WO2014173753A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8312507B2 (en) 2006-10-17 2012-11-13 A10 Networks, Inc. System and method to apply network traffic policy to an application session

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20011495A1 (it) 2001-07-12 2003-01-12 Pharmaproducts Uk Ltd Sali di calcio ad attivita' citotossica
ITMI20041279A1 (it) * 2004-06-24 2004-09-24 Pharmaproducts Uk Ltd Uso di calcio trifluoroacetato per la preparazione di medicamenti ad effetto anti-angiogenetico
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals

Also Published As

Publication number Publication date
TW201521716A (zh) 2015-06-16
EP2796135A1 (en) 2014-10-29
WO2014173753A1 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
ECSP15026557A (es) Compuestos y sus métodos de empleo
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
CL2016001933A1 (es) Compuestos derivados de macrociclos, inhibidores del factor xia composición farmacéutica que los comprende y su uso en el tratamiento yo profilaxis de una enfermedad tromboembolica. pct
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
MX2016012097A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
MX376329B (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
CL2016003260A1 (es) Profármacos de gemcitabina
CL2015002897A1 (es) Inhibidores de bace1
CL2016000436A1 (es) Método para el tratamiento de la enfermedad fibrótica
UY34775A (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple
UY35274A (es) Compuestos y métodos para tratar infecciones bacterianas
CL2015003019A1 (es) Derivados biaromáticos antibacterianos
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
UY34610A (es) Pirroldicarboxamidas condensadas y su uso como agentes farmacéuticos.
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas

Legal Events

Date Code Title Description
FB Suspension of granting procedure